Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

HHMI Bulletin May 2011 Sarah C. P. Williams	The Next Statin Although clinicians have firmly established the link between cholesterol levels and heart disease, there are still more questions than answers when it comes to the nitty-gritty molecular details of this connection.
The Motley Fool February 28, 2011 Brian D. Pacampara	Next-Generation Drug Technologies Battle It Out Alnylam and Sangamo BioSciences have different ways to manipulate proteins to fight disease.
Reactive Reports Issue 55 David Bradley	Testing the Byproducts of Cell Death A new approach to testing whether a particular chemotherapy agent is working well in treating a patient's cancer is being developed by UK scientists
Scientific American February 28, 2005 Gunjan Sinha	The Diet That Fits With the understanding that some diseases such as obesity are metabolic syndromes in which multiple biochemical pathways interact to cause complex symptoms, metabolic testing offers a way to gauge health over a lifetime.
Nutrition Action Healthletter April 1999	Cholestin Lowers Cholesterol It may be made from red yeast grown on rice, but over-the-counter Cholestin lowers blood cholesterol about as much as Mevacor and other prescription "statin" drugs...at about one-fifth the cost...
Bio-IT World July 14, 2004 Karen Hopkin	'Omics: The NextGeneration Researchers in industry and academia are cataloging collections of biochemical compounds (metabolomics) to determine how they respond when organisms are challenged by drugs, disease, or stress (metabonomics).
Chemistry World May 30, 2006 Michael Gross	A Physiological Role for Healthy Prions Researchers have shown that the healthy version of the scrapie pathogen helps maintain the optimum concentration of copper ions in the cell.
Chemistry World June 15, 2009 Matt Wilkinson	Concert arranges billion dollar GSK deal US-based Concert Pharmaceuticals has inked its first commercialization deal granting GlaxoSmithKline access to six deuterium-modified drugs
The Motley Fool March 14, 2006 Brian Gorman	AstraZeneca's Heartening News A new study shows cholesterol drug Crestor's further potential. Will it help sales?
Chemistry World May 18, 2015 Simon Hadlington	Opiate-producing yeast raises specter of 'home-brewed heroin' Science policy experts have called for urgent measures to be put in place to prevent strains of yeast that are capable of producing opiate drugs from falling into the hands of criminals.
Chemistry World December 2009	Column: In the pipeline Is the pharmaceutical industry churning out copycat versions of existing therapies? The author dispels a few myths about 'me-too' drugs
Chemistry World August 16, 2013 Paola Quattroni	Single molecule fights heart disease on two fronts Researchers in Israel have identified an antioxidant that can lower cholesterol levels as well as eliminating free radicals. This compound could be a promising alternative to statins, the most prescribed cholesterol-lowering drugs in the world.
Pharmaceutical Executive February 1, 2006 Ron Feemster	Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets.
American Journal of Nursing October 2009	Pharmacogenomics: Personalizing Drug Therapy Pharmacogenomics is a rapidly growing field of research into the ways in which genetic variation affects drug response.
The Motley Fool December 23, 2003 Arash Mostaghimi	The Cholesterol Wars Who will win the fight to save your arteries? Fortunately for our corpulent country, pharmaceutical companies want to unclog our arteries -- and lighten our wallets. But which pharma stock will add to most girth to a portfolio?
Nurse Practitioner August 2009 Linda A. Howe	Pharmacogenomics and management of cardiovascular disease Prior to the completion of the Human Genome Project in 2003, individual responses to medications were usually termed idiosyncrasies. Ethnic differences were not usually seen as genetic variants, as is the case today.
Chemistry World November 2010	Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?
Chemistry World July 11, 2008 Manisha Lalloo	Side-effects study opens up new drug leads Existing drugs could be used to treat a broader range of diseases, according to scientists in Germany and Denmark, who have predicted drug targets by using side-effects data on medication labels.
Chemistry World May 12, 2008 Simon Hadlington	'Super-yeast' tackles unnatural proteins Researchers in the US have engineered yeast cells to produce large amounts of proteins containing unnatural amino acids (UAAs) - a feat that has previously only been possible with bacteria.
The Motley Fool September 24, 2010 Brian Orelli	Prepare for This $12 Billion Whoosh Pfizer's Lipitor is the top-selling cholesterol drug -- in fact, it's the top selling drug period -- but it'll start to see generic competition in a little over a year.
The Motley Fool May 20, 2009 Brian Orelli	Clinical Trial Positive, Stock Not So Much Isis and Genzyme hit a homer with their cholesterol drug, mipomersen, but they'll need another big play to win the game.
BusinessWeek November 29, 2004 Catherine Arnst	Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs.
Managed Care April 2004 Jack McCain	Statin Therapy: More Than Meets the Eye? Statin selection has just become more complicated. Will physicians be diverted from interventions that may be less costly and just as effective?
BusinessWeek April 19, 2004 Catherine Arnst	Cholesterol: How Low Should It Be? New studies say as low as possible, but drugs aren't for everybody
Pharmaceutical Executive October 1, 2006 Rob Scott	Thoughtleader: Life After Lipitor A conversation with a former Pfizer executive who "launched the world's best-selling drug."
BusinessWeek November 22, 2004 Barrett & Carey	Wondering About A Wonder Drug While the benefits of statins, sold under names such as Lipitor and Zocor, are well established, some doctors argue that their side effects have not received adequate scrutiny.
Bio-IT World April 2007 Kevin Davies	The Human Metabolome Project Motivated by the absence of a metabolomic equivalent of GenBank that could provide information and possibly even samples of metabolites, researchers secured $7.5 million funding from Genome Canada in 2005 for the "Human Metabolome Project."
The Motley Fool April 24, 2008 Brian Orelli	Is Schering-Plough the Comeback Kid? Schering posts an OK quarter despite the slowdown in sales of its cholesterol drugs.
Chemistry World March 2011	60 years of innovation To celebrate the international year of chemistry, James Mitchell Crow looks back at some of the discoveries and developments made by chemists over the past six decades
The Motley Fool August 23, 2004 Ben McClure	Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest.
Chemistry World April 21, 2008 Pete Mitchel	The hunt for metabolic biomarkers In the largest metabonomics study ever carried out, researchers have discovered strong correlations between individuals' blood pressure and the levels of certain metabolites in their urine.
Scientific American June 2008 Melinda Wenner	Jeremy Nicholson's Gut Instincts: Researching Intestinal Bacteria The body and its intestinal flora produce chemicals with hidden health information, Jeremy Nicholson has found. Someday treating disease may mean treating those bacteria.
Chemistry World April 2011	Column: In the Pipeline If you look over the whole pharmacopeia, you'll see there are a lot of compounds that got their start as natural products.
Nutra Solutions April 1, 2006 Kerry Hughes	Additions to Heart Health The Portolio Eating Plan successfully assembles key nutritional ingredients known to lower cholesterol into one diet.
The Motley Fool April 2, 2008 Michael P. Cecil	Irrational Exuberance for Vytorin and Zetia? Drugmakers Merck and Schering-Plough certainly hoped data from the Enhance study would enhance the value and status of their blockbuster cholesterol-fighting drugs Zetia and Vytorin -- but its results did quite the opposite.
Bio-IT World April 15, 2003 Mark D. Uehling	Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials.
Scientific American November 14, 2005 Gunjan Sinha	Bugs and Drugs Gut bacteria could determine how well medicines work.
Chemistry World May 2008 Derek Lowe	In the pipeline The controversy over cholesterol drug Vytorin has been going on for months. Surveying the wreckage, my first thought is: what a terrible shame the whole affair is.
Chemistry World August 27, 2015 Phillip Broadwith	Drugs in a class of their own In the last month, three drugs in new therapeutic classes have been approved for cardiovascular diseases.
Information Today November 19, 2007	Thomson Healthcare Launches PDRhealth.com as Free Consumer Site The new PDRhealth.com is designed to put critical health information into the hands of consumers.
The Motley Fool April 29, 2008 Brian Orelli	Merck's Recovery Flushed Down Merck's best hope at recovery fails approval by the FDA.
Managed Care November 2004 Martin Sipkoff	OTC Status for Low-Dose Lovastatin Would Have Widespread Implications The FDA stands poised to approve OTC low-dose statins, following a similar change in United Kingdom.
The Motley Fool December 30, 2003 Arash Mostaghimi	Turning Cholesterol Into Cash With 62 million Americans suffering from heart disease, it's a huge target for major drug makers.
Chemistry World October 24, 2008 Hayley Birch	Proteins swap partners UK researchers have discovered that proteins which use metal cofactors can be surprisingly promiscuous metal binders, happily taking up the 'wrong' metal.
BusinessWeek November 24, 2010 Tom Randall	Merck May Have a Cholesterol Winner Merck told doctors at the American Heart Assn. annual meeting that new data showed its drug anacetrapib had reduced bad cholesterol by 40 percent while raising good cholesterol by an unprecedented 138 percent.
Chemistry World August 2009 Philip Ball	Column: The crucible Zinc nanoparticles appear to have the ability to make odorants smell stronger and could a give a valuable insight into how olfaction works
Reason September 2005 Kerry Howley	Locking Up Life-Saving Drugs U.S. prescription laws make us sicker and poorer because the system that puts drugs over the counter is driven by profits and patents.
Chemistry World August 11, 2008	Yeast Manufacture Morphine Precursor US scientists have developed a way to produce a group of medically important plant compounds in yeast. They say their technique could be used to manufacture drugs including painkillers and new cancer treatments.
The Motley Fool September 26, 2007 Brian Orelli	4 Platform Drugmakers to Watch Platform drugmakers have the potential to develop multiple drugs for a company. Let's take a look at four companies with good prospects: Abraxis BioScience... DURECT... Halozyme... Flamel Technologies...
The Motley Fool August 30, 2007 Brian Orelli	Merck Tries to Stop the Flushing The FDA will review the pharma's new cholesterol drug. The biggest worry with getting CORDAPTIVE approved is probably not with its effectiveness, but with safety. Investors, take note.